Related to FDA Performance

• FDA Hits Merck & Co. with Double Whammy for Gardasil Label Extensions
  
• FDA Clears Transgenically Produced Therapeutic
  
• FDA Stalls Approval of Genzyme’s Pompe Disease Drug
  
• Hologic Obtains FDA Nod for Two HPV Tests
  
• Orexo Receives FDA Green Light for Insomnia Drug
  
• Dyax Required to Submit More Data for FDA Approval of HAE Drug
  
• FDA Gives Arbor Vita’s Avian Flu Test the Go-Ahead
  
• Sanofi Pasteur's Flu Vaccine Manufacturing Plant Gets FDA Nod
  
• Novartis' Osteoporosis Drug Gets FDA Okay for Preventing Postmenopausal Osteoporosis
  
• FDA Orders Partial Clinical Hold on Genmab’s Anticancer Agent
  
• FDA Requires More Data to Approve ViroPharma’s Drug for Acute Treatment of Angioedema
  
• Novartis Gets FDA Okay for Drug to Treat Rare Inflammatory Disorder
  
• FDA Asks Spectrum Pharmaceuticals for Past Clinical Study Data to Help Expand Approval of NHL Drug
  
• Protalix’ Phase III Candidate for Gaucher’s May Fill the Treatment Gap due to Genzyme’s Plant Closure
  
• Shire’s Gaucher Disease Drug Candidate Being Considered by FDA
  
• FDA Gives Osmetech’s Cystic Fibrosis Genotyping Test a Thumbs Up
  
• Cepheid Gains FDA Approval for C. Difficile Molecular Diagnostic
  
• FDA Says Erbitux No Good for Those with Certain K-ras Mutations